An  	An  	 DT	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
efficacy  	efficacy  	 JJ	O
data  	data  	 NNS	O
from  	from  	 IN	O
four  	four  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
of  	of  	 IN	O
botulinum  	botulinum  	 JJ	B-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A-ABO  	A-ABO  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
A  	A  	 DT	O
new  	new  	 JJ	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
( 	( 	 -LRB-	O
BoNTA-ABO 	BoNTA-ABO 	 NNP	B-NP
;  	;  	 :	O
Dysport  	Dysport  	 NNP	B-NP
[ 	[ 	 -LRB-	O
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	B-NP
] 	] 	 -RRB-	O
,  	,  	 ,	O
Medicis  	Medicis  	 NNP	B-NP
Aesthetics 	Aesthetics 	 NNP	I-NP
,  	,  	 ,	O
Scottsdale 	Scottsdale 	 NNP	B-NP
,  	,  	 ,	O
AZ 	AZ 	 NNP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
recently  	recently  	 RB	O
been  	been  	 VBN	O
approved  	approved  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
United  	United  	 NNP	B-NP
States  	States  	 NNPS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
describe  	describe  	 VBP	O
the  	the  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
four  	four  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
four  	four  	 CD	O
studies  	studies  	 NNS	O
reported  	reported  	 VBD	O
here 	here 	 RB	O
,  	,  	 ,	O
three  	three  	 CD	O
were  	were  	 VBD	O
double-blind 	double-blind 	 JJ	B-NP
,  	,  	 ,	O
multicenter 	multicenter 	 NN	B-NP
,  	,  	 ,	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
studies  	studies  	 NNS	O
and  	and  	 CC	O
one  	one  	 PRP	O
was  	was  	 VBD	O
an  	an  	 DT	O
open-label  	open-label  	 JJ	B-NP
extension  	extension  	 NN	I-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
second  	second  	 JJ	O
phase  	phase  	 NN	O
III 	III 	 NNP	O
,  	,  	 ,	O
open-label  	open-label  	 JJ	B-NP
extension  	extension  	 NN	I-NP
study  	study  	 NN	I-NP
is  	is  	 VBZ	O
ongoing 	ongoing 	 JJ	O
.  	.  	 .	O
Studies  	Studies  	 NNS	O
enrolled  	enrolled  	 VBD	O
ethnically  	ethnically  	 RB	O
diverse 	diverse 	 JJ	O
,  	,  	 ,	O
healthy  	healthy  	 JJ	O
adults  	adults  	 NNS	O
with  	with  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
moderate  	moderate  	 JJ	O
severity  	severity  	 NN	O
at  	at  	 IN	O
maximum  	maximum  	 JJ	O
frown 	frown 	 NN	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
were  	were  	 VBD	O
followed  	followed  	 VBN	O
for  	for  	 IN	O
up  	up  	 RB	O
to  	to  	 TO	O
180  	180  	 CD	O
days  	days  	 NNS	O
after  	after  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
fixed-dose 	fixed-dose 	 JJ	B-NP
,  	,  	 ,	O
single  	single  	 JJ	O
treatment  	treatment  	 NN	B-NP
study  	study  	 NN	I-NP
randomized  	randomized  	 VBD	O
158  	158  	 CD	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
receive  	receive  	 VB	O
placebo  	placebo  	 NNS	O
or  	or  	 CC	O
a  	a  	 DT	O
single  	single  	 JJ	O
50-unit  	50-unit  	 CD	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
dose 	dose 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
fixed-dose 	fixed-dose 	 JJ	B-NP
,  	,  	 ,	O
repeat  	repeat  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
study  	study  	 NN	I-NP
enrolled  	enrolled  	 VBD	O
311  	311  	 CD	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
assess  	assess  	 VB	O
treatment  	treatment  	 NN	O
following  	following  	 VBG	O
repeat  	repeat  	 JJ	B-NP
BoNTA-ABO  	BoNTA-ABO  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
50  	50  	 CD	O
units 	units 	 NNS	O
.  	.  	 .	O
A  	A  	 DT	O
variable-dose  	variable-dose  	 JJ	B-NP
study  	study  	 NN	I-NP
randomized  	randomized  	 VBD	O
816  	816  	 CD	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
receive  	receive  	 VB	O
placebo  	placebo  	 NNS	O
or  	or  	 CC	O
a  	a  	 DT	O
single  	single  	 JJ	O
variable  	variable  	 JJ	O
dose  	dose  	 NN	O
( 	( 	 -LRB-	O
50  	50  	 CD	O
to  	to  	 TO	O
80  	80  	 CD	O
units 	units 	 NNS	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
muscle  	muscle  	 NN	B-NP
mass  	mass  	 NN	I-NP
assessment 	assessment 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
fourth  	fourth  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
study  	study  	 NN	O
was  	was  	 VBD	O
open-label  	open-label  	 JJ	B-NP
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
repeat  	repeat  	 NN	O
dosing  	dosing  	 NNS	O
( 	( 	 -LRB-	O
50  	50  	 CD	O
units 	units 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
evaluations  	evaluations  	 NNS	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
on  	on  	 IN	O
days  	days  	 NNS	O
14  	14  	 CD	O
and  	and  	 CC	O
30 	30 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
monthly  	monthly  	 JJ	O
thereafter 	thereafter 	 NN	O
.  	.  	 .	O
Primary  	Primary  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
endpoints  	endpoints  	 NN	I-NP
were  	were  	 VBD	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
investigators 	investigators 	 NNS	B-NP
'  	'  	 ''	O
and  	and  	 CC	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
line  	line  	 NN	I-NP
severity  	severity  	 NN	I-NP
at  	at  	 IN	O
day  	day  	 NN	O
30  	30  	 CD	O
using  	using  	 VBG	O
wrinkle  	wrinkle  	 JJ	B-NP
severity  	severity  	 NN	I-NP
rating  	rating  	 NN	I-NP
scales 	scales 	 NNS	I-NP
.  	.  	 .	O
Responders  	Responders  	 NNP	B-NP
were  	were  	 VBD	O
defined  	defined  	 VBN	O
as  	as  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
had  	had  	 VBD	O
a  	a  	 DT	O
composite  	composite  	 JJ	O
2+  	2+  	 CD	O
grade  	grade  	 NN	B-NP
improvement  	improvement  	 NN	I-NP
in  	in  	 IN	O
wrinkle  	wrinkle  	 JJ	B-NP
severity 	severity 	 NN	I-NP
,  	,  	 ,	O
meaning  	meaning  	 VBG	O
that  	that  	 IN	O
a  	a  	 DT	O
patient  	patient  	 NN	O
had  	had  	 VBD	O
a  	a  	 DT	O
baseline  	baseline  	 NN	B-NP
Glabellar  	Glabellar  	 NNP	I-NP
Line  	Line  	 NNP	I-NP
Severity  	Severity  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
GLSS 	GLSS 	 NNP	B-NP
)  	)  	 -RRB-	O
score  	score  	 NN	O
of  	of  	 IN	O
2  	2  	 CD	O
( 	( 	 -LRB-	O
moderate  	moderate  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
day  	day  	 NN	O
30  	30  	 CD	O
GLSS  	GLSS  	 JJ	B-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
0  	0  	 CD	O
( 	( 	 -LRB-	O
no  	no  	 DT	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
/ 	/ 	 JJ	I-NP
none 	none 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
a  	a  	 DT	O
baseline  	baseline  	 NN	B-NP
GLSS  	GLSS  	 NNP	I-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
3  	3  	 CD	O
( 	( 	 -LRB-	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
day  	day  	 NN	O
30  	30  	 CD	O
GLSS  	GLSS  	 JJ	B-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
0  	0  	 CD	O
( 	( 	 -LRB-	O
no  	no  	 DT	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
/ 	/ 	 JJ	I-NP
none 	none 	 NN	I-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
1  	1  	 CD	O
( 	( 	 -LRB-	O
mild  	mild  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
for  	for  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
blinded  	blinded  	 JJ	O
investigator 	investigator 	 NN	O
's  	's  	 POS	O
and  	and  	 CC	O
patient 	patient 	 NN	O
's  	's  	 POS	O
assessments 	assessments 	 NNS	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
( 	( 	 -LRB-	O
1116  	1116  	 CD	O
total 	total 	 NN	O
;  	;  	 :	O
720  	720  	 CD	O
BoNTA-ABO 	BoNTA-ABO 	 NN	B-NP
,  	,  	 ,	O
396  	396  	 CD	O
placebo 	placebo 	 CD	O
)  	)  	 -RRB-	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
received  	received  	 VBD	O
50  	50  	 CD	O
to  	to  	 TO	O
80  	80  	 CD	O
units 	units 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
median  	median  	 JJ	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
response  	response  	 NN	O
was  	was  	 VBD	O
85  	85  	 CD	O
days  	days  	 NNS	O
for  	for  	 IN	O
fixed  	fixed  	 JJ	O
dosing  	dosing  	 NN	O
and  	and  	 CC	O
109  	109  	 CD	O
days  	days  	 NNS	O
for  	for  	 IN	O
variable  	variable  	 JJ	O
dosing 	dosing 	 NN	O
.  	.  	 .	O
Similar  	Similar  	 JJ	O
efficacy  	efficacy  	 NN	O
occurred  	occurred  	 VBD	O
at  	at  	 IN	O
doses  	doses  	 NNS	O
adjusted  	adjusted  	 VBN	O
for  	for  	 IN	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
muscle  	muscle  	 NN	B-NP
mass 	mass 	 NN	I-NP
,  	,  	 ,	O
although  	although  	 IN	O
male  	male  	 JJ	O
patients  	patients  	 NNS	O
required  	required  	 VBN	O
higher  	higher  	 JJR	O
doses  	doses  	 NNS	O
than  	than  	 IN	O
female  	female  	 JJ	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
variable-dose  	variable-dose  	 JJ	B-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
Responses  	Responses  	 NNS	O
appeared  	appeared  	 VBD	O
as  	as  	 IN	O
early  	early  	 JJ	O
as  	as  	 IN	O
24  	24  	 CD	O
hours 	hours 	 NNS	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
median  	median  	 JJ	B-NP
time  	time  	 NN	I-NP
to  	to  	 TO	O
onset  	onset  	 VB	O
of  	of  	 IN	O
three  	three  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
open-label  	open-label  	 JJ	B-NP
extension  	extension  	 NN	I-NP
study  	study  	 NN	I-NP
evaluated  	evaluated  	 VBD	O
1200  	1200  	 CD	O
patients  	patients  	 NNS	O
for  	for  	 IN	O
13  	13  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
Maintenance  	Maintenance  	 NN	O
of  	of  	 IN	O
efficacy  	efficacy  	 NN	O
was  	was  	 VBD	O
seen  	seen  	 VBN	O
after  	after  	 IN	O
multiple  	multiple  	 JJ	O
treatment  	treatment  	 NN	B-NP
cycles 	cycles 	 NNS	I-NP
,  	,  	 ,	O
indicating  	indicating  	 VBG	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
did  	did  	 VBD	O
not  	not  	 RB	O
develop  	develop  	 VB	O
a  	a  	 DT	O
tolerance 	tolerance 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
second  	second  	 JJ	O
open-label  	open-label  	 JJ	B-NP
study  	study  	 NN	I-NP
is  	is  	 VBZ	O
ongoing  	ongoing  	 JJ	O
and  	and  	 CC	O
is  	is  	 VBZ	O
not  	not  	 RB	O
included  	included  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
report 	report 	 NN	O
.  	.  	 .	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
significantly  	significantly  	 RB	O
improved  	improved  	 VBN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
onset  	onset  	 NN	O
of  	of  	 IN	O
effect  	effect  	 NN	O
seen  	seen  	 VBN	O
as  	as  	 IN	O
soon  	soon  	 RB	O
as  	as  	 IN	O
24  	24  	 CD	O
hours  	hours  	 NNS	O
after  	after  	 IN	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
median  	median  	 JJ	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
effect  	effect  	 NN	O
of  	of  	 IN	O
85  	85  	 CD	O
and  	and  	 CC	O
109  	109  	 CD	O
days  	days  	 NNS	O
for  	for  	 IN	O
fixed  	fixed  	 JJ	O
and  	and  	 CC	O
variable  	variable  	 JJ	O
dosing 	dosing 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
